基尿作为一种粘附性疾病
1Health Education and Promotion Laboratory, Sorbonne Paris Nord University, Bobigny, France.
Patient preference and adherence
|April 18, 2025
概括
基尿症 (PKU) 可能是一种"粘附性疾病",其中高氨酸水平会损害认知功能,从而产生不粘附的循环. 这表明PKU本身阻碍了饮食遵守,影响神经认知.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 神经科学是一个神经科学.
- 患者坚持的研究研究.
背景情况:
- 基尿 (PKU) 是一种遗传性疾病,需要严格的饮食管理.
- 传统的坚持障碍包括可口性,成本,访问,时间和社会因素.
- 一个新的假设表明,PKU的病理生理学创造了一个恶化坚持的循环.
研究的目的:
- 探索PKU作为一种新的概念.
主要方法:
- 关于PKU病理生理学和坚持现有文献的叙事综述.
- 假设氨酸水平与执行功能之间存在反循环.
- 分析PKU对坚持能力的影响.
主要成果:
- 在非粘附性患者中,氨水平升高可能会损害认知和执行功能.
- 这种障碍可能会降低坚持必要的低氨饮食的能力.
- PKU的病理生理学可能会创造一个恶性循环,加剧坚持挑战.
结论:
- 由于其自我恶化的性质,PKU可能被认为是"粘附性疾病".
- 长期不坚持饮食可能在PKU中很常见.
- 恢复氨氨酸氧酶活性是缓解PKU神经认知和心理社会影响的关键.
相关概念视频
Inborn Errors of Metabolism
109
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
109
Overview of Protein Metabolism
529
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
529
Factors Affecting Protein-Drug Binding: Patient-Related Factors
31
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
31
Protein-Drug Binding: Mechanism and Kinetics
144
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
144
Drug Distribution: Plasma Protein Binding
4.4K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
4.4K
Allosteric Proteins-ATCase
5.6K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K


